IMVT

Immunovant Inc. (IMVT) | Rumor.io

Immunovant

IMVT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,971

Bullish sentiment (50-day avg)39%

Price to earnings ratio-12.1

Market capitalization6.9B

Earnings per share-2.81

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-505.6M

Social

What share of all stock conversation is about IMVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 23

Immunovant, Inc. ($IMVT) announced topline results from a proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus erythematosus, which did not achieve statistical significance on its primary endpoint.
The study showed numerical trends favoring IMVT-1402 over placebo, but due to the competitive landscape and clinical results, Immunovant plans to stop development in CLE.
Immunovant's stock fell by almost 10% after the trial results were announced, with some investors questioning the company's valuation and pipeline progress.

Generated by AI

Sentiment

Of the messages about IMVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -88.89	13.04% -69.31	80% +17.52
Bearish	—	100% +88.89	86.96% +69.31	20% -17.52

Bullish· May 21

Immunovant's IMVT-1402 has shown impressive Phase 2b trial results, with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36% in rheumatoid arthritis patients.
Immunovant has a strong financial position with $7.3B in cash and a peak revenue potential of $6.8B for IMVT-1402, driven by growth in the global dermatology and rheumatology markets.
The company's focused Phase 3 development plan and $902M cash reserve make it a well-funded and strategic player in the biotech industry, with a strong narrative for long-term growth.

Bearish· Mar 19

Immunovant's ($IMVT) data has been objectively bad, with a weaker placebo-adjusted response in myasthenia gravis (MG) compared to Argenx ($ARGX).
The company's decision to raise $500 million at $20 a share when the stock was at $24 a month prior suggests a lack of confidence in the asset's value.
The high dose of Immunovant's treatment may have won in some trials, but the sell-side models still break because they're leaving out bato, suggesting the results may not be as significant as they seem.

Generated by AI

Topics

Of the messages about IMVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.59%	70.01%
Technical Analysis	—	0%	0%	16.16%
Analysts	—	0%	7.41%	6.71%
Macro	—	0%	0%	3.56%
Controversies	—	0%	0%	0.58%
Earnings	—	0%	0%	2.98%

Analysts· Jun 2

Credit Suisse analyst Tiago Fauth maintains Immunovant (IMVT) with a Neutral rating and lowers the price target from $26 to $12.
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (IMVT) with a Buy rating and lowers the price target from $23 to $19.
Analysts are very confident about Immunovant (IMVT), with a 98% buy consensus among 10 analysts.

Announcements· May 20

Immunovant's lead asset, IMVT-1402, has shown strong preliminary Week 16 results in difficult-to-treat rheumatoid arthritis, with response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70.
The company has reported its fiscal fourth-quarter and full-year 2026 financial results, highlighting a net loss of $147.9M in Q4 and $505.6M for the full year, with cash reserves of $902.1M as of March 31.
Immunovant has discontinued its batoclimab program and is focusing on IMVT-1402, which is advancing in multiple Phase 3 programs, including Graves' disease, myasthenia gravis, Sjögren's disease, and CIDP.

Generated by AI

Community

Of the messages about IMVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	85.15%	86.8%	50.42%
Newcomers	—	14.85%	13.2%	49.58%

Regulars· Sep 23

Immunovant's lead asset IMVT-1402 suffered its first clinical setback in a proof-of-concept study for cutaneous lupus erythematosus, missing its primary endpoint.
The study's results prompted Immunovant to discontinue development of IMVT-1402 for the CLE indication, despite numerical trends favoring the treatment over placebo across multiple endpoints.
The company will continue to develop other programs, and the discontinuation of IMVT-1402 will not impact Immunovant's overall pipeline or its $7.7B market capitalization.

Newcomers· Jul 23

Newcomers are debating whether to hold onto Immunovant, Inc. despite the recent drop, with some questioning the long-term story and others looking for a rebound setup.
Many are reevaluating their thesis and considering cutting losses, with some even thinking about the potential for a longer downtrend.
Traders are weighing their options, with some considering averaging down and others looking for an entry point, and there is uncertainty about whether insiders are buying or selling.

Generated by AI

Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication. Despite observing numerical trends favoring IMVT-1402 and better responses in patients with deeper IgG reductions, Immunovant concluded that the combination of these data and a competitive treatment...

5h agoYahoo Finance

Immunovant (IMVT) Just Gave Investors Something To Think About

Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued. The mixed trial outcome lands at a sensitive moment for Immunovant. The share price is US$33.49 after a 1-day share price return of 0.57%, yet the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. This hints that recent traders have been...

1d agoYahoo Finance

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference […]

2d agoYahoo Finance

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

4d agoMorningstar

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)

Tipranks Press Release.

5d agoThe Globe and Mail

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

5d agoYahoo Finance UK

Also Discussed

Investors talking about IMVT also mention

#	Name	Attention
1	Roivant Sciences Ltd.ROIV	0%new
2	Crinetics Pharmaceuticals IncCRNX	0%0
3	argenx SE American Depositary ReceiptARGX	0%0
4	BridgeBio Pharma Inc.BBIO	0.01%0
5	iShares Nasdaq-100 ex Top 30 ETFQNXT	0%0
6	UFP Technologies Inc.UFPT	0%0
7	BioAge Labs, Inc.BIOA	0%-0.13
8	MeiraGTx Holdings plcMGTX	0%new
9	Nurix Therapeutics, Inc.NRIX	0%new
10	Arcus Biosciences, Inc.RCUS	0%new

Immunovant Inc.

Healthcare
Biotechnology

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.

Website

Location

1000 Park Forty Plaza

Durham, NC, 27713

United States

Social

What share of all stock conversation is about IMVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 23

Immunovant, Inc. ($IMVT) announced topline results from a proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus erythematosus, which did not achieve statistical significance on its primary endpoint.
The study showed numerical trends favoring IMVT-1402 over placebo, but due to the competitive landscape and clinical results, Immunovant plans to stop development in CLE.
Immunovant's stock fell by almost 10% after the trial results were announced, with some investors questioning the company's valuation and pipeline progress.

Generated by AI

Sentiment

Of the messages about IMVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -88.89	13.04% -69.31	80% +17.52
Bearish	—	100% +88.89	86.96% +69.31	20% -17.52

Bullish· May 21

Immunovant's IMVT-1402 has shown impressive Phase 2b trial results, with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36% in rheumatoid arthritis patients.
Immunovant has a strong financial position with $7.3B in cash and a peak revenue potential of $6.8B for IMVT-1402, driven by growth in the global dermatology and rheumatology markets.
The company's focused Phase 3 development plan and $902M cash reserve make it a well-funded and strategic player in the biotech industry, with a strong narrative for long-term growth.

Bearish· Mar 19

Immunovant's ($IMVT) data has been objectively bad, with a weaker placebo-adjusted response in myasthenia gravis (MG) compared to Argenx ($ARGX).
The company's decision to raise $500 million at $20 a share when the stock was at $24 a month prior suggests a lack of confidence in the asset's value.
The high dose of Immunovant's treatment may have won in some trials, but the sell-side models still break because they're leaving out bato, suggesting the results may not be as significant as they seem.

Generated by AI

Topics

Of the messages about IMVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.59%	70.01%
Technical Analysis	—	0%	0%	16.16%
Analysts	—	0%	7.41%	6.71%
Macro	—	0%	0%	3.56%
Controversies	—	0%	0%	0.58%
Earnings	—	0%	0%	2.98%

Analysts· Jun 2

Credit Suisse analyst Tiago Fauth maintains Immunovant (IMVT) with a Neutral rating and lowers the price target from $26 to $12.
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (IMVT) with a Buy rating and lowers the price target from $23 to $19.
Analysts are very confident about Immunovant (IMVT), with a 98% buy consensus among 10 analysts.

Announcements· May 20

Immunovant's lead asset, IMVT-1402, has shown strong preliminary Week 16 results in difficult-to-treat rheumatoid arthritis, with response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70.
The company has reported its fiscal fourth-quarter and full-year 2026 financial results, highlighting a net loss of $147.9M in Q4 and $505.6M for the full year, with cash reserves of $902.1M as of March 31.
Immunovant has discontinued its batoclimab program and is focusing on IMVT-1402, which is advancing in multiple Phase 3 programs, including Graves' disease, myasthenia gravis, Sjögren's disease, and CIDP.

Generated by AI

Community

Of the messages about IMVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	85.15%	86.8%	50.42%
Newcomers	—	14.85%	13.2%	49.58%

Regulars· Sep 23

Immunovant's lead asset IMVT-1402 suffered its first clinical setback in a proof-of-concept study for cutaneous lupus erythematosus, missing its primary endpoint.
The study's results prompted Immunovant to discontinue development of IMVT-1402 for the CLE indication, despite numerical trends favoring the treatment over placebo across multiple endpoints.
The company will continue to develop other programs, and the discontinuation of IMVT-1402 will not impact Immunovant's overall pipeline or its $7.7B market capitalization.

Newcomers· Jul 23

Newcomers are debating whether to hold onto Immunovant, Inc. despite the recent drop, with some questioning the long-term story and others looking for a rebound setup.
Many are reevaluating their thesis and considering cutting losses, with some even thinking about the potential for a longer downtrend.
Traders are weighing their options, with some considering averaging down and others looking for an entry point, and there is uncertainty about whether insiders are buying or selling.

Generated by AI

Immunovant

Social

Sep 23

Bullish· May 21

Bearish· Mar 19

Analysts· Jun 2

Announcements· May 20

Regulars· Sep 23

Newcomers· Jul 23

Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next

Immunovant (IMVT) Just Gave Investors Something To Think About

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Also Discussed

Immunovant Inc.

Company Information

Location

Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next

Immunovant (IMVT) Just Gave Investors Something To Think About

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Also Discussed

Social

Sep 23

Bullish· May 21

Bearish· Mar 19

Analysts· Jun 2

Announcements· May 20

Regulars· Sep 23

Newcomers· Jul 23